Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
all over itchy body rash; This non-serious case was reported by a consumer and described the occurrence of itchy rash in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of rash pruritic (1at dose received on 14-JAN-2026). On 11-APR-2026, the patient received the 2nd dose of Shingrix. On 11-APR-2026, less than a day after receiving Shingrix, the patient experienced itchy rash (Verbatim: all over itchy body rash). The patient was treated with hydrocortisone acetate, pramocaine hydrochloride (Hydroxine) and clobetasol propionate (Clobetasol). Rechallenge with Shingrix was positive. On 30-MAY-2026, the outcome of the itchy rash was resolved (duration 1 month 19 days). It was unknown if the reporter considered the itchy rash to be related to Shingrix. Linked case(s) involving the same patient: US2026077442 Additional Information: GSK receipt date 10-JUN-2026 The batch number was not provided upon follow- up with the reporter.; Sender's Comments: US-GSK-US2026077442:case created for 1 dose